31 – 40 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008.
(
- Contribution to journal › Article
- 2010
-
Mark
Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenstrom Macroglobulinemia.
(
- Contribution to journal › Article
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study
(
- Contribution to journal › Article
-
Mark
Monoclonal Gammopathy of Undetermined Significance and Risk of Infections A Population Based Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
(
- Contribution to journal › Article
-
Mark
The Success Story of Targeted Therapy In Chronic Myeloid Leukemia A Population Based Study of 3,173 Patients Diagnosed In Sweden 1973-2008
(
- Contribution to journal › Published meeting abstract
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(
- Contribution to journal › Published meeting abstract
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
Highly increased familial risks for specific lymphoma subtypes
(
- Contribution to journal › Article